当前位置: 首页 > 期刊 > 《医学信息》 > 2016年第32期
编号:12990193
吉西他滨联合替吉奥治疗晚期胰腺癌疗效观察(2)
http://www.100md.com 2016年8月13日 《医学信息》 2016年第32期
     参考文献:

    [1]夏金堂,徐波.胰腺癌非手术治疗的现状和展望[J].实用医学杂志,2010,26(10):1685-1687.

    [2]Murakami Y,Uemura K,Sudo T,et al.Adjuvant gemcitabine plus S-1 chemotberapy after surgical resection for pancreatic adenocarcinoma[J].Am J Surg,2008,195:757-762.

    [3]Murakami Y,Uemura K,Sudo T,et al.Impact gemcitabine plus S-1 chemotberapy after surgical resection for adenocarcinoma of the luxly or tail of the pancreas[J].J Gas-trointest surg,2009,13:85-92.

    [4]郭春光,赵平.胰腺癌分子靶向治疗进展[J].癌症进展,2008,6(1):25.

    [5]Tanaka F,Fukuse T,Wada H,et al.The history,mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agants[J].Curr Pharm Biotechnol,2000,1:137-164.

    [6]Shirasaka T,Shimamato Y,Ohshimo H,et al.Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J].Antiancer Drugs,1996,7:548-557.

    [7]Nakamura K,Yamaguchi T,Ishihara T,et al,Phase II trial of oral S-l combined with gemcitabine in metastatic pancreatic pancreatic cancer[J].Br J Cancer,2006,94(11):1575-1579.

    編辑/周芸霏, 百拇医药(张颖 邵玲玲)
上一页1 2